Latigo Biotherapeutics reported Q3 2026 results, highlighting progress in its non-opioid pain drug development. The company is on track to start Phase 3 trials for onzotrigine, including a new opioid comparator arm with Percocet, aiming to provide an alternative to opioid pain relief. Phase 2 trials for LTG-321, targeting chronic pain, are ongoing with topline results expected in late 2027. With $401 million in cash, Latigo is financially positioned to fund operations through 2029, supporting its pipeline advancement and clinical programs.
Latigo Biotherapeutics reported Q3 2026 financial results and business highlights, including progress in non-opioid pain drug development and a cash position of $401 million to fund operations through 2029. For readers following the health sector, here is Pluang's market snapshot as of Nov 05, 2026 18:11 WIB: out of 150 priced US health stocks, 85 rose and 56 fell. Notable movers include ACHC at USD 34.05 (+5.58%), RVMD at USD 210.09 (+5.20%), and LFST at USD 14.88 (+4.71%).
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping chann...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
